AZD4205 is a JAK1-selective kinase inhibitor which is in clinical development for oncology rather than the inflammatory diseases most JAK1 inhibitors have aimed for. The compound has excellent PK in dog, and the authors demonstrate that JAK1 inhibition doesn’t have strong single-agent activity in a xenograft model but can synergize
< 1 minute read
Sep. 17, 2021
AZD4205: a JAK1-selective kinase inhibitor in clinical development for oncology
AZD4205
JAK1-selective kinase inhibitor in clinical development for cancer from HTS and SBDD of promiscuous hit J. Med. Chem., Apr. 28, 2020 AstraZeneca, Waltham, MA